Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank50
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-47.11M
↑ 21% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-59.76M
Historical baseline
PeriodValueYoY Change
2025$-47.11M-133.3%
2024$-20.20M+74.6%
2023$-79.63M-16.8%
2022$-68.17M-30.0%
2021$-52.44M-34.2%
2020$-39.09M+60.1%
2019$-98.06M+4.0%
2018$-102.17M-82.8%
2017$-55.90M-60.5%
2016$-34.84M-